Cara Therapeutics to Present Late-Breaking Poster at Kidney Week 2015

SHELTON, Conn., Oct. 29, 2015 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that its Chief Medical Officer, Joseph Stauffer, D.O., M.B.A., will present a late-breaking poster at Kidney Week 2015, the American Society of Nephrology’s Annual Meeting. The event will be held November 5-8, 2015 at the San Diego Convention Center.

Details for the late-breaking poster are as follows:

Title: “CR845, a Novel Kappa Opioid Receptor Agonist, Reduces Moderate-to-Severe Pruritus and Improves Quality of Life in Chronic Kidney Disease Patients Undergoing Hemodialysis”

Poster Number: SA-PO1117

Session: Late-Breaking Posters

Location: Exhibit Hall A, San Diego Convention Center

Date: Saturday, November 7, 2015

Time: 10:00 a.m. – 12:00 p.m. PT

For more information on Kidney Week 2015, visit https://www.asn-online.org/education/kidneyweek/.

About CR845

CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In more than 440 subjects dosed to date, I.V. CR845 was observed to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists. Cara recently initiated its Phase 3 program with I.V. CR845 in postoperative pain. Cara also has an ongoing Phase 2 trial of an oral tablet formulation of CR845, for the treatment of osteoarthritis (OA).

In Q3’15, Cara announced positive results with I.V. CR845 in a Phase 2 trial in uremic pruritus patients where CR845 treatment resulted in statistically significant reductions in both the primary endpoint of worst itching and secondary endpoints assessing quality of life measurements.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated activity in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

CONTACT: INVESTOR CONTACT:
         Jesse Baumgartner
         Stern Investor Relations, Inc.
         212-362-1200
         Jesse@sternir.com
        
         MEDIA CONTACT:
         Annie Starr
         6 Degrees
         973-415-8838
         astarr@6degreespr.com

Left Menu Icon
Right Menu Icon